The THOR project (2021-2023) aimed to build a knowledge base for development of the next generation of anti-atherosclerotic drugs. Smooth muscle cells play a central role in the development of atherosclerosis and therefore the THOR team et out to identify both genes and biological pathways that modulate the role of smooth muscle cells in atherosclerosis development.
The THOR team combined both human genetic studies with functional studies on smooth muscle cells in the lab and they identified a set of candidate genes and associated pathways, which may be intersting targets for drug therapy of atherosclerosis.
On this page you can can watch a video recorded at the beginning of the THOR project. You can also read an article on the output of the project.
THE THOR TEAM
Academic team members
- Jacob Fog Bentzon, Professor, Aarhus University
- Mette Nyegaard, Professor, Aalborg University
- Julian Albarrán-Juárez, Asst. Professor, Aarhus University
- Anton Markov, postdoc, Aarhus University
- Lisa Maria Røge
- Sidsel Hauge Bøttcher
Industrial team members
- Michael Nyberg, Novo Nordisk
- Giulia Borghetti, Novo Nordisk
- Kate Herum, Novo Nordisk
- Anna Uryga, Novo Nordisk
- Julian Bachmann, Novo Nordisk
- Djorde Djordevic, Novo Nordisk
- Line Jessen, Novo Nordisk
ABOUT ODIN
We unite bright minds from industry and academia to jointly create need-driven clinical research projects - and pave the way for innovative new treatments and diagnostics. We fund the best project ideas through competitive funding calls. Although companies cannot receive funding, it is free of charge to join.
The platform is sponsored by the Novo Nordisk Foundation with 180 million DKK from 2024-2029.
CONTACT ODIN
You are welcome to contact us if you have questions or comments. Reach out to odin@au.dk or find the Secretariat's direct email addresses under contacts.
Although the platform spans five Danish universities, we're based in Aarhus. Our office is located at Aarhus University, Ny Munkegade 120, blg 1521-214.
